Basel Medical Group Ltd
BMGL
$0.77
-$0.09-10.37%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.63% | 8.12% | 3.03% | 3.97% | 4.84% |
| Total Other Revenue | 107.69% | 171.42% | 759.35% | 754.30% | 749.26% |
| Total Revenue | 18.07% | 11.61% | 6.52% | 7.47% | 8.36% |
| Cost of Revenue | 54.27% | 52.84% | 53.75% | 28.73% | 7.15% |
| Gross Profit | -28.79% | -33.70% | -37.08% | -16.03% | 9.96% |
| SG&A Expenses | 9.16% | -10.22% | -21.69% | -27.82% | -33.91% |
| Depreciation & Amortization | 127.35% | 74.99% | 23.47% | 9.34% | -3.73% |
| Other Operating Expenses | 242.78% | 272.99% | 340.97% | 163.55% | 38.71% |
| Total Operating Expenses | 72.88% | 63.70% | 55.72% | 27.52% | 2.86% |
| Operating Income | -148.88% | -119.51% | -96.03% | -47.85% | 29.48% |
| Income Before Tax | -629.95% | -310.12% | -95.84% | -54.63% | 13.01% |
| Income Tax Expenses | -228.42% | -153.64% | -128.88% | -96.10% | -5.86% |
| Earnings from Continuing Operations | -694.03% | -354.32% | -83.12% | -41.87% | 16.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -694.01% | -354.31% | -83.12% | -41.87% | 16.75% |
| EBIT | -148.88% | -119.51% | -96.03% | -47.85% | 29.48% |
| EBITDA | -144.12% | -116.85% | -94.97% | -47.20% | 29.06% |
| EPS Basic | -555.86% | -293.13% | -83.12% | -41.84% | 16.91% |
| Normalized Basic EPS | -147.15% | -116.57% | -95.87% | -54.63% | 13.04% |
| EPS Diluted | -555.86% | -293.13% | -83.12% | -41.84% | 16.91% |
| Normalized Diluted EPS | -147.15% | -116.57% | -95.87% | -54.63% | 13.04% |
| Average Basic Shares Outstanding | 15.60% | 7.80% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 15.60% | 7.80% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |